Detailed View
HALO - Halozyme Therapeutics, Inc.
Latest filing: 2026-06-30 | Reporting: gaap
Market Cap
12,231,372,800
Adj EBIT (TTM)
660,267,000
Enterprise Value
14,214,888,800
Last Price
103.12
Earnings Yield
4.64%
Return on Capital
90.60%
Capital
728,794,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-06-30 | 10-Q | 2026 | 480,999,000 | 287,654,000 |
| 2026-03-31 | 10-Q | 2026 | 376,708,000 | 184,517,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 451,767,000 | -92,891,000 |
| 2025-09-30 | 10-Q | 2025 | 354,264,000 | 217,921,000 |
| 2025-06-30 | 10-Q | 2025 | 325,719,000 | 202,441,000 |
| 2025-03-31 | 10-Q | 2025 | 264,861,000 | 141,535,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 298,008,000 | 175,501,000 |
| 2024-09-30 | 10-Q | 2024 | 290,084,000 | 163,197,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.